Quantum Dot Biomimetic for SARS-CoV-2 to Interrogate Blood–Brain Barrier Damage Relevant to NeuroCOVID Brain Inflammation
Source abstract
Abstract
Despite limited evidence for infection of SARS-CoV-2 in the central nervous system, cognitive impairment is a common complication reported in "recovered" COVID-19 patients. Identification of the origins of these neurological impairments is essential to inform therapeutic designs against them. However, such studies are limited, in part, by the current status of high-fidelity probes to visually investigate the effects of SARS-CoV-2 on the system of blood vessels and nerve cells in the brain, called the neurovascular unit. Here, we report that nanocrystal quantum dot micelles decorated with spike protein (COVID-QDs) are able to interrogate neurological damage due to SARS-CoV-2. In a transwell co-culture model of the neurovascular unit, exposure of brain endothelial cells to COVID-QDs elicited an inflammatory response in neurons and astrocytes without direct interaction with the COVID-QDs. These results provide compelling evidence of an inflammatory response without direct exposure to SARS-CoV-2-like nanoparticles. Additionally, we found that pretreatment with a neuro-protective molecule prevented endothelial cell damage resulting in substantial neurological protection. These results will accelerate studies into the mechanisms by which SARS-CoV-2 mediates neurologic dysfunction.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Long-Term Effects of COVID-19 · Quantum Dots Synthesis And Properties · SARS-CoV-2 and COVID-19 Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina 27710, United States
Funding
Division of Chemistry · NIH Office of the Director · American Heart Association · National Institutes of Health
References (69)
Show source-provided references
1. 10.3389/fimmu.2021.73275610.3389/fimmu.2021.732756 ↗
2. 10.1021/acschemneuro.0c0021710.1021/acschemneuro.0c00217 ↗
3. 10.1038/s41593-020-00758-510.1038/s41593-020-00758-5 ↗
4. 10.1126/sciadv.abc580110.1126/sciadv.abc5801 ↗
5. 10.1073/pnas.202435811810.1073/pnas.2024358118 ↗
6. 10.1177/175909142095496010.1177/1759091420954960 ↗
7. 10.1007/s10787-021-00806-x10.1007/s10787-021-00806-x ↗
8. 10.1038/s41593-020-00771-810.1038/s41593-020-00771-8 ↗
9. 10.1016/j.nbd.2020.10513110.1016/j.nbd.2020.105131 ↗
10. 10.1186/1471-2180-10-16510.1186/1471-2180-10-165 ↗
11. 10.1073/pnas.190256311610.1073/pnas.1902563116 ↗
12. 10.1016/j.jddst.2020.10209410.1016/j.jddst.2020.102094 ↗
13. 10.1038/nmat139010.1038/nmat1390 ↗
14. 10.1038/nmeth.124810.1038/nmeth.1248 ↗
15. 10.1021/acs.jpcb.0c1154510.1021/acs.jpcb.0c11545 ↗
16. 10.1021/nl061165u10.1021/nl061165u ↗
17. 10.1021/acsnano.0c0597510.1021/acsnano.0c05975 ↗
18. 10.1021/acs.nanolett.9b0510310.1021/acs.nanolett.9b05103 ↗
19. 10.1021/jacs.1c0936310.1021/jacs.1c09363 ↗
20. 10.1021/jacs.9b1197810.1021/jacs.9b11978 ↗
21. 10.1016/j.chemphys.2015.09.01010.1016/j.chemphys.2015.09.010 ↗
22. 10.1021/acsphotonics.8b0061710.1021/acsphotonics.8b00617 ↗
23. 10.1021/jacs.5b0476510.1021/jacs.5b04765 ↗
24. 10.1039/c9bm01629e10.1039/c9bm01629e ↗
25. 10.1021/acs.accounts.9b0064110.1021/acs.accounts.9b00641 ↗
26. 10.1021/nn305189n10.1021/nn305189n ↗
27. 10.1021/acs.nanolett.9b0248310.1021/acs.nanolett.9b02483 ↗
28. 10.1016/j.jlr.2021.10012910.1016/j.jlr.2021.100129 ↗
29. 10.1186/s12951-021-00806-710.1186/s12951-021-00806-7 ↗
30. 10.1021/acs.nanolett.0c0446510.1021/acs.nanolett.0c04465 ↗
31. 10.1016/s0140-6736(20)31185-510.1016/s0140-6736(20)31185-5 ↗
32. 10.1038/s41598-022-04883-y10.1038/s41598-022-04883-y ↗
33. 10.3390/vaccines906055410.3390/vaccines9060554 ↗
34. 10.1523/JNEUROSCI.0598-13.201310.1523/JNEUROSCI.0598-13.2013 ↗
35. 10.1186/s12974-019-1582-510.1186/s12974-019-1582-5 ↗
36. 10.1096/fj.202200184RR10.1096/fj.202200184RR ↗
37. 10.1039/c8sc03355b10.1039/c8sc03355b ↗
38. 10.1021/jp511893210.1021/jp5118932 ↗
39. 10.1021/nn400282510.1021/nn4002825 ↗
40. 10.1038/nprot.2007.35110.1038/nprot.2007.351 ↗
41. Saeboe A. M. · 2020 · 9510.1007/978-1-0716-0463-2_5 ↗
42. 10.1038/s41586-020-2665-210.1038/s41586-020-2665-2 ↗
43. 10.1002/jps.2015010.1002/jps.20150 ↗
44. 10.1021/nl050017l10.1021/nl050017l ↗
45. 10.1002/anie.20046149110.1002/anie.200461491 ↗
46. 10.1021/nl201978c10.1021/nl201978c ↗
47. 10.1021/acsomega.7b0028810.1021/acsomega.7b00288 ↗
48. 10.1039/c8nr05099f10.1039/c8nr05099f ↗
49. 10.1007/s11481-020-09975-y10.1007/s11481-020-09975-y ↗
50. 10.1083/jcb.20141214710.1083/jcb.201412147 ↗
51. 10.1038/s41598-019-56163-x10.1038/s41598-019-56163-x ↗
52. 10.1016/j.jid.2019.06.14510.1016/j.jid.2019.06.145 ↗
53. 10.1177/0271678X1774079310.1177/0271678X17740793 ↗
54. 10.1016/j.bbi.2005.10.00510.1016/j.bbi.2005.10.005 ↗
55. 10.1038/s41419-021-03465-610.1038/s41419-021-03465-6 ↗
56. 10.1172/jci2544410.1172/jci25444 ↗
57. 10.1038/nature1277610.1038/nature12776 ↗
58. 10.1074/jbc.m113.50291410.1074/jbc.m113.502914 ↗
59. 10.3892/mmr.2020.1151010.3892/mmr.2020.11510 ↗
60. 10.1186/s11658-022-00311-110.1186/s11658-022-00311-1 ↗
61. 10.1038/s42003-022-03237-810.1038/s42003-022-03237-8 ↗
62. 10.1242/jcs.21935210.1242/jcs.219352 ↗
63. 10.1038/s41467-017-00037-110.1038/s41467-017-00037-1 ↗
64. 10.1038/s41421-021-00293-y10.1038/s41421-021-00293-y ↗
65. 10.1038/s41421-021-00302-010.1038/s41421-021-00302-0 ↗
66. 10.1212/nxi.000000000000114610.1212/nxi.0000000000001146 ↗
67. 10.1021/ja103805s10.1021/ja103805s ↗
68. 10.1021/nl502699710.1021/nl5026997 ↗
69. 10.1021/bc300399f10.1021/bc300399f ↗